GlassScriptPhysician profile
Pramern Sriratana
NPI 1174522189
$17,706.87
in general payments reported to CMS, 2019-2025
57 companies · $3,798 in 2025
The $3,798 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,170 · 2020: $692 · 2021: $1,679 · 2022: $2,847 · 2023: $3,032 · 2024: $4,488 · 2025: $3,798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,897 · Long Term Medical Supply Or Device Loan: $1,513 · Education: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,896.94 |
| Long Term Medical Supply Or Device Loan | $1,513.35 |
| Education | $907.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,625.44 | 2020-2025 | |
| Janssen Biotech, INC. | $2,118.92 | 2019-2025 | Tecvayli, Darzalex, Erleada |
| Astrazeneca Pharmaceuticals LP | $1,913.77 | 2019-2025 | Imfinzi, Lynparza, Enhertu |
| Genentech USA, INC. | $1,652.65 | 2019-2025 | Tecentriq, Polivy, Lunsumio |
| Merck Sharp & Dohme LLC | $1,572.25 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $666.60 | 2019-2025 | |
| Abbvie INC. | $589.44 | 2021-2025 | Venclexta |
| Daiichi Sankyo INC. | $579.60 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Lilly USA, LLC | $531.38 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $500.15 | 2020-2025 | Opdivo, Opdualag |
| Astellas Pharma US INC | $383.20 | 2019-2025 | Padcev, Xospata, Vyloy |
| Celgene Corporation | $357.96 | 2019-2025 | Pomalyst, Reblozyl, Empliciti |
| Eisai INC. | $342.26 | 2020-2025 | |
| Genzyme Corporation | $305.40 | 2020-2025 | |
| Gilead Sciences, INC. | $301.55 | 2021-2025 | Trodelvy |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $280.24 | 2021-2025 | Lumakras |
| Tempus Ai, INC | $244.68 | 2024-2025 | Xt Cdx |
| Exelixis INC. | $205.84 | 2023-2025 | Cabometyx |
| Seagen INC. | $205.04 | 2020-2024 | Padcev |
| Incyte Corporation | $194.02 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Alexion Pharmaceuticals, INC. | $176.27 | 2019-2025 | Ultomiris |
| Jazz Pharmaceuticals INC. | $130.67 | 2023-2025 | Zepzelca |
| Array Biopharma INC | $127.76 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Beigene USA, INC. | $120.21 | 2022-2024 | Brukinsa, Tevimbra |
| Regeneron Healthcare Solutions, INC. | $107.64 | 2022-2025 | Libtayo |
| Glaxosmithkline, LLC. | $102.83 | 2020-2023 | Zejula, Jemperli, Ojjaara |
| Pharmacyclics LLC, An Abbvie Company | $97.85 | 2019-2022 | |
| Progenics Pharmaceuticals, INC. | $92.67 | 2023 | Pylarify |
| Sobi, INC | $79.84 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $79.58 | 2019-2022 | |
| Aveo Pharmaceuticals, INC. | $75.87 | 2021-2023 | Fotivda |
| Beone Medicines USA, INC. | $74.67 | 2025 | Brukinsa, Tevimbra |
| Genmab U.S., INC. | $72.57 | 2022-2025 | Epkinly |
| Taiho Oncology, INC. | $65.43 | 2023-2025 | |
| Adc Therapeutics America, INC. | $63.39 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.88 | 2024-2025 | Iclusig |
| Foundation Medicine, INC. | $55.33 | 2019 | |
| Blueprint Medicines Corporation | $53.53 | 2024-2025 | Ayvakit |
| Janssen Pharmaceuticals, INC | $48.52 | 2021-2022 | |
| Mirati Therapeutics, INC. | $36.65 | 2023 | Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $36.26 | 2025 | |
| Agios Pharmaceuticals, INC. | $35.53 | 2022 | |
| Pharmacosmos Therapeutics INC. | $32.47 | 2025 | Monoferric |
| Syndax Pharmaceuticals, INC. | $31.40 | 2025 | |
| Azurity Pharmaceuticals, INC. | $28.93 | 2025 | Danziten, Vivimusta |
| Puma Biotechnology, INC. | $28.70 | 2019-2021 | |
| Rigel Pharmaceuticals, INC. | $26.62 | 2019-2024 | Rezlidhia, Tavalisse |
| Karyopharm Therapeutics INC. | $25.95 | 2023 | Xpovio |
| Tersera Therapeutics LLC | $23.62 | 2025 | Zoladex |
| Tolmar, INC. | $23.00 | 2025 | Eligard |
| Epizyme, INC. | $22.91 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.23 | 2025 | |
| G1 Therapeutics, INC. | $18.07 | 2022 | |
| Caris Mpi, INC. | $17.03 | 2025 | Mi Cancer Seek |
| Stemline Therapeutics INC. | $17.00 | 2025 | Orserdu |
| Servier Pharmaceuticals LLC | $16.63 | 2025 | |
| Acrotech Biopharma INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pramern Sriratana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.